- Home
- DSY vs IMMX Comparison
DSY vs IMMX Comparison
Compare DSY & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- IMMX
- Stock Information
- Founded
- DSY 2020
- IMMX 2014
- Country
- DSY China
- IMMX United States
- Employees
- DSY N/A
- IMMX N/A
- Industry
- DSY
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- DSY
- IMMX Health Care
- Exchange
- DSY Nasdaq
- IMMX Nasdaq
- Market Cap
- DSY 85.8M
- IMMX 82.6M
- IPO Year
- DSY N/A
- IMMX 2021
- Fundamental
- Price
- DSY $0.47
- IMMX $4.31
- Analyst Decision
- DSY
- IMMX Strong Buy
- Analyst Count
- DSY 0
- IMMX 1
- Target Price
- DSY N/A
- IMMX $8.00
- AVG Volume (30 Days)
- DSY 213.6K
- IMMX 842.3K
- Earning Date
- DSY 01-01-0001
- IMMX 11-07-2025
- Dividend Yield
- DSY N/A
- IMMX N/A
- EPS Growth
- DSY 120.37
- IMMX N/A
- EPS
- DSY 0.01
- IMMX N/A
- Revenue
- DSY $7,323,356.00
- IMMX N/A
- Revenue This Year
- DSY N/A
- IMMX N/A
- Revenue Next Year
- DSY N/A
- IMMX N/A
- P/E Ratio
- DSY $38.58
- IMMX N/A
- Revenue Growth
- DSY 16.37
- IMMX N/A
- 52 Week Low
- DSY $0.47
- IMMX $1.34
- 52 Week High
- DSY $7.33
- IMMX $4.60
- Technical
- Relative Strength Index (RSI)
- DSY 23.40
- IMMX 66.99
- Support Level
- DSY $0.47
- IMMX $3.16
- Resistance Level
- DSY $0.61
- IMMX $4.60
- Average True Range (ATR)
- DSY 0.03
- IMMX 0.43
- MACD
- DSY 0.00
- IMMX 0.06
- Stochastic Oscillator
- DSY 4.01
- IMMX 79.99
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.